The effect of gavage or intravenous (i.v.) administration of sodium chlorate salts on the fecal shedding of generic Escherichia coli in wether lambs was studied. To this end, 9 lambs (27 ± 2.5 kg) were administered 150 mg NaClO 3 /kg BW by gavage or i.v. infusion in a crossover design with saline-dosed controls. The crossover design allowed each animal to receive each treatment during 1 of 3 trial periods, resulting in 9 observations for each treatment. Immediately before and subsequent to dosing, jugular blood and rectal fecal samples were collected at 4, 8, 16, 24, and 36 h. Endpoints measured were fecal generic E. coli concentrations, blood packed cell volume (PCV), blood methemoglobin concentration, and serum and fecal sodium chlorate concentrations. Sodium chlorate had no effects (P > 0.05) on blood PVC or methemoglobin. Fecal generic E. coli concentrations were decreased (P < 0.05) approximately 2 log units (99%) relative to controls 16 and 24 h after sodium chlorate infusion and 24 h after sodium chlorate gavage. Within and across time and treatment, fecal chlorate concentrations were highly variable for both gavage and i.v. lambs. Average fecal sodium chlorate concentrations never exceeded 100 µg/g and were typically less than 60 µg/g from 4 to 24 h after dosing. Times of maximal average fecal sodium chlorate concentration did not correspond with times of lowered average generic E. coli concentrations. Within route of administration, serum sodium chlorate concentrations were greatest (P < 0.01) 4 h after dosing; at the same time point, serum chlorate was greater (P < 0.01) in i.v.-dosed lambs than gavaged lambs but not at 16 or 24 h (P > 0.05). At 8 h, serum chlorate concentrations of gavaged lambs were greater (P < 0.05) than in i.v.-dosed lambs. Serum chlorate data are consistent with earlier studies indicating very rapid transfer of orally dosed chlorate to systemic circulation, and fecal chlorate data are consistent with earlier data showing the excretion of low to marginal concentrations of sodium chlorate in orally dosed animals. Efficacy of sodium chlorate at reducing fecal E. coli concentrations after i.v. infusion suggests that low concentrations of chlorate in gastrointestinal contents, delivered by biliary excretion, intestinal cell sloughing, or simple diffusion, are effective at reducing fecal E. coli levels. Alternatively, chlorate could be eliciting systemic effects that influence fecal E. coli populations.
INTRODUCTION
Numerous studies have demonstrated that oral administration of chlorate salts decreases the numbers of pathogenic and nonpathogenic Escherichia coli shed in feces of food animals (reviewed by . It has been assumed that chlorate salts interact directly with microbes within the gastrointestinal (GI) lumen to reduce bacterial numbers, presumably because several studies have demonstrated that chlorate is effective in both pure and mixed culture. However, multiple studies have documented the rapid and extensive removal of chlorate from the GI contents of several species through absorption (Smith et al., 2005 (Smith et al., , 2006 . As chlorate levels in GI tracts decrease, there is concomitant and rapid increase of chlorate in serum (Oliver et al., 2007; of orally dosed animals. Thus, GI absorption effectively removes chlorate from the presumed site of action. demonstrated that ewes excreted less than 5% of a massive 450 mg/kg BW dose of chlorate in feces over a 48 h period whereas over 67% was excreted unchanged in the urine.
Escherichia coli and other potentially pathogenic organisms are present in intestinal luminal contents, in intestinal mucosa, and in enteric (Naylor et al., 2003; Bonardi et al., 2007; Baines et al., 2008; Keen et al., 2010) and peripheral (Brichta-Harhay et al., 2012) lymph tissues. Because serum levels of sodium chlorate can reach concentrations greater than are found in intestinal contents, it is possible that chlorate could be delivered to intestinal microenvironments via the circulatory system by transfer through the highly perfused lamina propria or by entry into the lymphatic system. If such a supposition were true, then the intravenous (i.v.) administration of chlorate salts would tend to reduce fecal E. coli concentrations in a manner similar to orally dosed animals and would provide insights into the site or sites of chlorate action against potential food pathogens. Therefore, the objective of this study was to determine the effect of chlorate administration route, i.v. vs. gavage, on the concentration of generic E. coli in sheep feces and to determine concentrations of chlorate salts in serum and feces of dosed animals.
MATERIALS AND METHODS

Animals
An animal use protocol was reviewed and approved by the Biosciences Research Laboratory Institutional Animal Care and Use Committee before the receipt of experimental animals. Nine wether lambs (27 ± 2.5 kg) were transported from the USDA-ARS U.S. Sheep Experiment Station near Dubois, ID, to Fargo, ND. Subsequent to housing in concrete-floored barn facilities, animals had ad libitum access to a grass-alfalfa hay mixture and water; sheep were fed 0.5 kg of cracked corn daily at times coincidental with training to head gates.
Experimental Design and Treatments
A crossover design was used in which each animal was scheduled to receive each of three treatments during three trial periods (Table 1) . Treatments were no sodium chlorate (Control; lambs received i.v. infusion and gavage of saline), i.v. sodium chlorate (i.v.; lambs received i.v. infusion of 150 mg NaClO 3 /kg BW and gavage of saline), and oral gavage of sodium chlorate (gavage; lambs received i.v. infusion of saline and gavage of 150 mg NaClO 3 /kg BW). Lambs were assigned randomly to 1 of 3 groups of three each. Lambs within each group were scheduled to receive each of the three treatments for each of three trial periods according to a Latin square design with periods as rows and lambs as columns. Periods were separated by a minimum of 14 d. Because the serum half-life of chlorate in sheep is roughly 6 h , a washout period of 14 d (48 half-lives) was more than adequate to allow the complete elimination of residual chlorate from test animals. Likewise, the cecal doubling time of E. coli is sufficiently short (120 min; Rang et al., 1999) that 14 d washout periods (J. B. Taylor, unpublished data) were adequate to allow fecal E. coli numbers to rebound.
Treatment Formulation
A 50 mg/mL sodium chlorate (>99%; Sigma-Aldrich, St. Louis, MO) stock solution, prepared in nanopure water (>18 mΩ cm), was used to formulate i.v. and gavage sodium chlorate doses. For i.v. doses, the appropriate volume of stock solution was combined with a proper volume of physiologic saline (0.9%; Abbott Laboratories, North Chicago, IL) to provide 150 mg/kg BW NaClO 3 in a total volume of 250 mL. To this end, 250-mL i.v. bags of saline were used and the volume of chlorate required for dosing was removed using a syringe. The volume of saline removed was replaced with the sodium chlorate stock solution so that each i.v. bag contained 250 mL total volume. Gavaged sodium chlorate was delivered to animals as undiluted stock solution (see below). Doses were prepared based on the weight of each lamb approximately 16 h before dosing.
Catheter Placement
Approximately 1 to 2 h before the initiation of each study period, sheep were restrained in head gates, and 18-gauge, 6.25-cm catheters (Milacath, Erlanger, KY) were placed in jugular veins. Upon placement, each catheter was flushed with sterile heparinized saline (heparin sodium salt; 350 U/mL; Sigma-Aldrich; St. Louis, MO), capped, and secured to the skin using a drop of acrylic glue.
Gavage
Within lamb, gavage was always performed just before the initiation of i.v. infusion. In addition to placement in a head gate, lambs were further restrained with a halter; stomach tubes (product number 553400; Premier 1 Supply, Washington, IA) were placed into the rumen and lambs were dosed with the appropriate volume of sodium chlorate or with saline using a 60-mL syringe (Becton-Dickinson, Franklin Lakes, NJ). The volume of saline gavaged into Control animals was equivalent to the volume of chlorate stock solution required for a lamb of corresponding BW.
Intravenous Dose Administration
Outlets of i.v. bags containing sodium chlorate or saline were pierced with an in-line flow regulator (Abbott Laboratories) and connected to jugular catheters with 198 cm primary i.v. sets (Abbott Laboratories). Sodium chlorate (150 mg/kg BW) or saline was flow regulated to deliver 250 mL in 3 h or less. At the completion of the infusion period, each jugular catheter was removed before lambs were released from head gates.
Blood Collection
Blood was collected through 21-gauge needles from jugular veins at 0, 4, 8, 16, 24, and 36 h into one 4-mL tube with heparin (Becton Dickinson) and one 10-mL tube with a clotting activator (Becton Dickinson). Tubes with heparin were gently inverted 8 times, placed immediately on ice, and subsequently used for methemoglobin and packed cell volume (PCV) determinations. Serum tubes were inverted 5 times, allowed to clot for 30 min, and centrifuged for 10 min at 1,200 × g (5°C); serum was removed and stored at -20°C for sodium chlorate analysis.
Fecal Collections
Fecal grab samples were collected from each sheep at 0, 4, 8, 16, 24, and 36 h relative to the start of infusion. Fecal samples (5 to 25 g) were collected from the rectum of each sheep using sterile gloves and feces were placed into sterile 50-mL polypropylene tubes (Sarstedt, Newton, NC). Tubes were placed on ice and transported immediately to a laboratory for enumeration of E. coli.
Fecal material not used for bacterial counts was frozen for chlorate analyses. Fecal grab samples were also taken from all animals before the initiation of the study to establish baseline generic E. coli levels.
Enumeration of Generic Escherichia coli
Generic E. coli were determined using Petrifilm E. coli plates (3M, St. Paul, MN) after serial dilution (to 10 -7 ) of fecal matter extracts in sterile PBS (pH 7.2). For each sheep and time point, duplicate 2.0 ± 0.05-g aliquots of feces were weighed into sterile Whirl-Pak bags (Nasco, Ft. Atkinson, WI) and diluted in 18.0 mL of sterile PBS. The contents of each bag were mixed for 2 min at high speed using a Seward-80 paddle blender (Seward, West Sussex, England). Subsequent to mixing, 1-mL aliquots (Falcon 1-mL pipettes; Becton-Dickinson) of the fecal slurries were serially diluted to 10 -7 in 9-mL volumes of sterile PBS contained in 16-by 100-mm borosilicate glass tubes. Dilutions were mixed, and aliquots (1 mL) of each dilution were plated onto labeled Petrifilm E. coli plates (3M) according to the manufacturer's instructions. Petrifilm plates were incubated for 24 h at 35°C. Colonies were enumerated by direct visualization.
Packed Cell Volume
Duplicate replicates of heparinized blood from each sheep at each time point were drawn into 75-mm hematocrit tubes (Daigger, Vernon Hills, IL) until tubes were approximately two-thirds full. Each tube was sealed with clay and centrifuged at for 5 min on a microcapillary centrifuge (12,700 × g at room temperature; Damon/IEC, Needham, MA). The percentage PCV of each tube was determined with the aid of a hematocrit reader card (Midwest Veterinary Supply, Burnsville, MN) and recorded.
Methemoglobin
Methemoglobin (mHb) was measured in duplicate within 1 h of blood collection using the colorimetric method of Evelyn and Malloy (1938) as modified by Hegesh et al. (1970) . have described the validation of the methemoglobin analysis in sheep serum.
Chlorate Analyses
Blood and fecal serum chlorate was determined using liquid chromatography mass spectrometry as described by Smith and Taylor (2011) . Briefly, the mass spectral method used an 18 O-labeled internal standard (Smith and Taylor, 2011 ) and a matrix-matched calibration curve. Serum assay volumes for mass spectral analyses were 0.2 mL with a cor-responding method limit of quantification of 0.067 µg/mL; less serum sample was used during repeat analyses for samples whose concentrations exceeded the range of the standard curve during an initial analysis. Fecal assays used 1 g of sample, with a corresponding method limit of quantification of 0.1 µg/g. Fecal samples that returned chlorate values greater than the highest standard of the standard curve were re-run with lesser amount of samples. Because of relatively high concentrations of chlorate, serum samples collected at 4 and 8 h were assayed using the colorimetric procedure described by Smith and Taylor (2011) .
Statistics
For analyses of fecal E. coli data (cfu/g of feces), SAS/ STAT software, version 9.3 (SAS Institute Inc., Cary, NC) was used. Blocking factors were period and lamb, and the experimental unit was lamb within period; square was included in the model as a random effect. A linear mixed model was fit using SAS/STAT software, version 9.3 (Proc GLIMMIX) to compare log transformed means (cfu/g) of E. coli among treatments within time point. The repeated measures covariance structure was fitted with a heterogeneous autoregressive model as this was determined with likelihood ratio tests to account for within animal correlation (χ 2 = 37.6, df = 1, P < 0.0001) and heterogeneity of variance (χ 2 = 15.6, df = 5, P < 0.0081) among time points.
For serum and fecal sodium chlorate concentrations, plasma methemoglobin, and PCV, data were analyzed using 2-way ANOVA with main effects of treatment and time (GraphPad Prism 6.00; GraphPad Software, La Jolla. CA). For the analysis of serum sodium chlorate residues, the 2-way ANOVA was conducted using only the 4, 8, 16, and 24 h time points of the oral and i.v. treatments; the 0 and 36 h data were not included because too few data points were above the method limit of quantification (LOQ). Fecal chlorate residues were analyzed in a similar manner as serum residues with the exception that the 24-h data were not included because too few values were above the LOQ. Figure 1A shows the effect of sodium chlorate administration route on fecal E. coli concentrations. Control treatment (i.e., saline) did not influence fecal E. coli concentrations (P = 0.99). In contrast, fecal E. coli concentrations were reduced (P < 0.05) relative to Control concentrations at 16 and 24 h for the i.v. sodium chlorate treatments and at 24 h for the oral treatment. Fecal E. coli concentrations in the i.v. and gavage treatments did not differ (P > 0.05) from each other at 16 or 24 h; at 16 h the gavage group did not differ from the Control group (P > 0.05). By 36 h, concentrations of generic E. coli in feces of i.v. and gavage lambs were not different (P > 0.05) from concentration in feces from Control lambs.
RESULTS
Fecal Escherichia coli
Fecal and Serum Sodium Chlorate
Concentrations of sodium chlorate in feces and serum are shown in Table 2 and are summarized in Fig. 1B and 1C. Within route of dose, serum chlorate residues were greatest at the 4-h sample (P < 0.01) and decreased rapidly with time. Chlorate levels were greater (P < 0.01) for the i.v. treated lambs than the gavaged lambs at 4 h but not at 16 or 24 h (P > 0.05); serum chlorate from gavaged lambs was greater (P < 0.05) than serum chlorate of i.v.-dosed lambs at 8 h. Measured concentrations of serum chlorate were highest at the 4 h sampling point, averaging 194 µg/ mL for lambs given sodium chlorate by i.v. infusion and 139 µg/mL for sodium chlorate administered by gavage.
Fecal chlorate residues were measurable at the 4 h sampling point in lambs treated with sodium chlorate by i.v. infusion or gavage, averaging 17 µg/g for the i.v. treatment and 1.1 µg/g for the gavaged lambs. Maximal chlorate concentrations in feces for lambs treated by i.v. infusion occurred at the 8 h sampling point with lambs excreting feces averaging 100 µg/g sodium chlorate; in sodium chlorate gavaged lambs, fecal chlorate residues at 8 and 16 h were identical at 52 µg/g. Animal-to-animal variations in concentrations of fecal sodium chlorate at each time point were great with coefficients of variation (not shown) typically being greater than 100%.
Methemoglobin and Packed Cell Volume
Values for methemoglobin in sheep serum were never greater than 1% across treatment and sampling period (data not shown). Control blood tubes, fortified with sodium nitrate [to form mHb] and diluted with normal blood to create theoretical mHb equivalents of 1.25 and 2.5%, returned mHb values of 0.8 ± 0.1 and 2.3 ± 0.4%, respectively (n = 3 per determination). Figure 2 shows the effect of treatment on PCV values, which were not affected (P > 0.05) by treatment.
DISCUSSION
Methemoglobin and PCV, toxicological endpoints associated with chlorate poisoning (reviewed by , were not changed relative to Controls after oral or i.v. chlorate administration. Therefore, as a single acute dose (150 mg/kg BW), chlorate was well tolerated, consistent with other studies indicating that single exposures to chlorate are generally well tolerated in sheep J. B. Taylor, unpublished data) .
Fecal E. coli concentrations responded to oral gavage chlorate administration in a manner consistent with previous responses of E. coli, pathogenic E. coli serotypes, and/or Salmonella in sheep Edrington et al., 2003; Taylor et al., 2012) , cattle Callaway et al., 2002) , and swine (Anderson et al., , 2004 . That is, concentrations of fecal indicator organisms typically drop by 2 to 3 log units 16 to 24 h after dosing. In this study, E. coli levels decreased approximately 2 log units, or about 99%, by 16 h after chlorate administration. By 24 h, E. coli levels had rebounded ( Fig. 1A) but were still lower than E. coli eliminated from Control lambs. The 150 mg/kg BW dose of sodium chlorate provided in this study was much lower than that used by Edrington et al. (2003) and was bracketed by the 30 and 450 mg/kg BW doses used by Taylor et al. (2012) . had previously demonstrated sodium chlorate activity against generic E. coli in sheep given a single, oral, 150 mg/kg BW dose of sodium chlorate. Therefore, the reduction of fecal E. coli after oral administration of 150 mg NaClO 3 /kg BW demonstrated that the positive Control treatment, gavaged chlorate, had expected effects on fecal E. coli concentrations. The mechanism through which chlorate exerts its toxigenic effect or effects on gram-negative pathogens is believed to be through the actions of membrane-bound respiratory nitrate reductases. That is, nitrate reductase, which normally converts nitrate to nitrite under anaerobic conditions, may co-metabolize chlorate (ClO 3 -) to chlorite (ClO 2 -; Pichinoty et al., 1969; Stewart, 1988) . Chlorite is considered to be the ultimate toxin in exposed bacteria and it has been indirectly (Pichinoty et al., 1969) and directly (Goksøyr, 1952; Smith et al., 2009 ) measured in cultures of chlorate exposed bacteria. Although aerobes and anaerobes may produce a number of nitrate reductases, only the membrane bound nitrate reductases are believed to metabolize chlorate (Bell et al., 1990 (Bell et al., , 1993 . If production of chlorite from chlorate through nitrate reductase is the sole mechanism of chlorate efficacy in food animals, then it is reasonable to expect that the direct contact of chlorate and susceptible microbes must occur for chlorate to be effective in the GI tract.
Our data clearly indicate that chlorate salts delivered via i.v. infusion were as effective as gavaged sodium chlorate in reducing fecal shedding of E. coli (Fig. 1A) . Intravenous infusions were designed to deliver the complete chlorate dose within 3 h, to be consistent with previous work demonstrating that serum chlorate levels peak between 1 and 3 h after oral gavage of sheep . As might be expected, serum chlorate levels in infused lambs were greater (P < 0.05) than serum chlorate levels in gavaged lambs at 4 h posttreatment but not at later time points. Given the timing of sampling after dose administration, the appearance and depletion of sodium chlorate in the blood was remarkably similar between the dose routes.
In sheep, as in other animal species, the major route of chlorate elimination is through urinary excretion, and fecal elimination is a minor excretory route (reviewed by . The appearance of chlorate in feces of i.v. dosed lambs in this study indicates that chlorate salts had some mechanism for entry into the GI tract. The most obvious route for chlorate entry after i.v. infusion is through biliary excretion. In fact, some evidence does exist for chlorate entry into the GI tract via the biliary route. For instance, bile from cattle orally dosed with either 62 or 130 mg/kg BW of sodium 36 Cl-chlorate and slaughtered 8 h after dosing contained 191 and 240 µg/g of chlorate equivalents (Smith et al., 2005) . In addition, swine dosed orally with 20, 40, or 60 mg/kg BW of sodium 36 Cl-chlorate (Smith et al., 2006) and slaughtered 24 h after exposure had bile that contained 0 to 7 µg/g sodium chlorate equivalents. However, for both studies, biliary radioactive residues were not speciated and it is unknown whether biliary radioactivity was present as chlorate or chloride ion. Assuming that the entire quantity of biliary radioactivity was parent chlorate, it is unclear what fraction would be available for transport to the lower portions of the GI tract and subsequent excretion in feces; the GI tract has a large capacity for chlorate absorption, and bile enters into the upper region of the duodenum. Therefore, for the i.v.-treated lambs of this study, the presence of chlorate in feces does not necessarily indicate that bile was the source of fecal chlorate. Additional sources of fecal chlorate in i.v. dosed lambs could be through intestinal sloughing of the epithelial layer of the lower tract or by simple diffusion from the lamina propria. However, it is hard to estimate the quantitative contributions that epithelial sloughing and/ or diffusion would have to luminal chlorate concentrations.
Concentrations of chlorate salts in fecal materials after gavage or i.v. chlorate administration were highly variable (Table 2) and were relatively dilute, with the greatest concentration occurring 8 h after dosing at 100 µg/g in the i.v.-treated group. In gavaged lambs, chlorate content of feces averaged 52 µg/g at both the 8 and 16 h sampling times. Although these concentrations may not necessarily be indicative of the peak levels of chlorate in fecal material (which could have occurred at times other than 8 or 16 h), they are consistent with levels of fecal chlorate in other studies with similar oral chlorate doses . Of note is the apparent rapidity at which chlorate was measurable in fecal matter of i.v.-treated lambs.
It is not clear if fecal chlorate concentrations measured in this study were great enough to have directly caused the observed decreases of fecal E. coli concentration. Previous in vitro studies have used greater concentrations of sodium chlorate to elicit antibacterial effects. For instance, growth of E. coli O157:H7 was not greatly affected by 0.5 or 1 mM (53 and 106 µg/mL) sodium chlorate in tryptic soy broth cultures or by 1 mM chlorate in fresh fecal extracts after 8 h, but growth was markedly reduced at 5 mM (530 µg/mL) sodium chlorate in both pure and mixed cultures al., 2009). Anderson et al. (2000) demonstrated that 1.25 mM (133 µg/mL) of sodium chlorate reduced the concentrations E. coli O157:H7 or Salmonella by about 2.5 log units during in vitro ruminal fluid incubations buffered at pH 6.8. However, in ruminal fluid buffered at pH 5.6, 1.25 mM sodium chlorate was marginally or temporarily effective. Chlorate was also effective at reducing generic E. coli and Salmonella concentrations in swine fecal cultures, but chlorate was tested only at 5 mM (530 µg/mL) concentrations and greater. Based on the preponderance of the available evidence, the levels of chlorate measured in sheep feces of this study were only marginally sufficient to account for the reductions in E. coli in feces excreted by sheep.
In addition to the marginal concentrations of chlorate in feces, it is of interest to note that the time points associated with the greatest fecal concentrations of sodium chlorate were not associated with the lowest levels of fecal E. coli (Fig. 1A and 1B) . That is, at the 16 and 24 h sampling times, when E. coli numbers were reduced after i.v. chlorate administration (P < 0.05), fecal chlorate concentrations were roughly 45 µg/g and less than 3 µg/g, respectively. In fact, at 24 h, only one sheep from the i.v. treatment had measurable fecal chlorate. Collectively, concentration and activity data suggest that chlorate may be having affects other than or in addition to direct affects on microbes within the lumen of the GI tract. Circumstantial data may support such a supposition. For example, Patchanee et al. (2007) and Anderson et al. (2004) documented that oral sodium chlorate reduced the prevalence and percentage of ileocolic lymph nodes testing positive for Samonella pathogens. Because high concentrations of chlorate are present in blood serum and because the electrolytic composition of interstitial fluid is nearly identical to lymph (Hall, 2010) it is highly likely that chlorate is delivered to mesenteric lymph nodes through the systemic circulation and possibly through absorption.
Mechanisms through which chlorate might cause a systemic effect are speculative at best, but for years it has been known that chlorate is an inhibitor of ATP-sulfurylase, the initial enzyme in the cellular synthesis of 3′-phosphoadenosine 5′-phosphosulfate (Baeuerle and Huttner, 1986) . 3′-Phosphoadenosine 5′-phosphosulfate is the "obligate" cofactor for intercellular sulfotransferase enzymes, which catalyze the addition of sulfate to a myriad of substrates (Klaassen and Boles, 1997) . Of importance to this discussion is the fact that sulfated glycans, present on epithelial surfaces throughout the body, are hypothesized to play a critical role in the adherence of numerous microbial species to host targets during invasion and infection (Rostand and Esko, 1997; Wadström and Ljungh, 1999) . For example, the binding of varied pathogens including Bordetella (Menozzi et al., 1994) , Toxplasma gondii (Jacquet et al., 2001) , Chlamydia trachomatis (Fadel and Eley, 2004) , and Encephalitozoon intestinalis (Hayman et al., 2005) to several cell models has been attributed to specific interactions with sulfated proteoglycans, interactions that are specifically disrupted by the inhibition of sulfation by chlorate. Therefore, one might expect that if chlorate acts systemically it could do so in altering lymphatic and intestinal mucosal mucin composition. That is, because chlorate is an effective inhibitor posttranslational sulfation of GI mucins (Dekker et al., 1989; Liau et al., 1992) and because both commensal and enteropathogenic bacteria colonize intestinal mucin (Bergstrom et al., 2010) , it is not unreasonable to theorize that the disruption of mucosal sulfation by chlorate could temporarily disrupt colonization-and any competitive advantage gained by colonization-of chlorate susceptible bacteria.
To our knowledge, this study is the first demonstration that parenteral administration of sodium chlorate affects the shedding of fecal bacteria. Although we do not anticipate that parenteral administration will be a viable route for dosing chlorate salts in commercial food-safety applications, the data nevertheless provide some insight into the possible mechanism or mechanisms of chlorate action in live animals and give an indication of the physiologic location at which the inorganic anion may be active.
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